Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Two Patent Applications Related to RNAi: Jul 17, 2008

Premium
Title: Modulation of Biological Signal Transduction by RNA Interference
 
Number: 7,399,586
 
Filed: May 23, 2003
 
Lead Inventor: Richard Klinghoffer, Ceptyr
 
According to the patent’s abstract, the invention comprises “compositions and methods relating to small interfering RNA polynucleotides … as pertains to modulation of biological signal transduction … [including] siRNA polynucleotides that interfere with expression of members of the protein tyrosine phosphatase class of enzymes that mediate signal transduction, and with certain MAP kinase kinases. In certain preferred embodiments, siRNA modulate signal transduction pathways comprising SHP2, cdc14a/b, cdc25A/B/C, KAP, PTP-epsilon, PRL-3, CD45, dual specificity phosphatase-3, MKK-4, and/or MKK-7. Modulation of PTP-mediated biological signal transduction has uses in diseases associated with defects in cell proliferation, cell differentiation, and/or cell survival, such as metabolic disorders (including diabetes and obesity), cancer, autoimmune disease, infectious and inflammatory disorders, and other conditions,” the abstract notes. “The invention also provides siRNA polynucleotides that interfere with expression of chemotherapeutic target polypeptides, such as DHFR, thymidylate synthetase, and topoisomerase I.”
 

 
Title: Method and Medicament for Inhibiting the Expression of a Given Gene
 
Number: 20080166800
 
Filed: Oct. 31, 2007
 
Lead Inventor: Roland Kreutzer, Alnylam Europe (Alnylam Pharmaceuticals)
 
“The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA,” the patent application’s abstract states.
 

 
Title: Cancer Therapy Via the Inhibition of Skp-2 Expression
 
Number: 20080167256
 
Filed: March 22, 2005 PCT Filed: March 22, 2005
 
Lead Inventor: Hidetoshi Sumimoto, Keio University School of Medicine
 
The invention comprises “a double-stranded RNA capable of suppressing expression of Skp-2 gene, a double-stranded RNA expression cassette capable of expressing a double-stranded RNA, a double-stranded RNA expression vector containing a double-stranded RNA expression cassette, and highly safe therapeutic drug and therapy specific to cancers such as small cell lung cancer having Skp-2 as a molecular target,” the patent application’s abstract states. “The RNAi target sequence is set in a plurality of sites in the protein translation region of Skp-2 mRNA, the expressed siRNA, which is a dsRNA exhibiting RNAi effect, is constructed on a lentiviral vector to construct a recombinant viral vector, and various small cell lung cancer cell lines and small cell lung cancers are infected with this viral vector, to confirm the cell proliferation suppression effect in vitro and the proliferation suppression effect in vivo.”